Objectives. To develop and coordinate protocols for chemotherapy regimens in a large integrated healthcare organization; to disseminate protocols in a timely fashion; to maintain protocols for continuous quality improvement; and to promote utilization of protocol-based chemotherapy.
Methods. Two interdisciplinary groups reviewed the acceptability, accessibility, and appropriateness of the existing protocols, and proposed recommendations to be implemented by the Systemic Therapy Program of the agency.
Results. A standard protocol format and a pharmacist-coordinated protocol system were developed. Protocols were relocated from the Intranet to the network computer directory and Internet website for increased accessibility. To date, 172 protocols are available on the network directory and the website, with 87% (150/172) reviewed by pharmacists and physicians of an interdisciplinary review panel. Preliminary analysis shows increased healthcare professionals’ satisfaction and a protocol use in 77% of patients treated.
Conclusion. A pharmacist-coordinated chemotherapy protocol system improves protocol dissemination, protocol compliance, and chemo-therapy delivery and safety. The project enhances the pharmacist profile and credibility within the organization.
National Library of Medicine Medical Subject Headings 2000 MeSH Descriptor Data. Clinical protocols. Available from http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/patents.html. Accessed 23 August 2000.
2.
Meadows AT, Kramer S, Hopson R, et al.Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment. Cancer Invest1983; 1: 49-55.
3.
Karjalainen S, Palva I.Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland [see comments]. BMJ1989; 299: 1069-1072.
Cancer Care Ontario Practice Guidelines Initiative. Clinical practice guidelines. Available from http://hiru.mcmaster.ca/ccopgi/guidelines.html. Accessed 10 October 2001.
6.
National Comprehensive Cancer Network. NCCN oncology practice guidelines. Available from http://www.nccn.org/guidelines.htm. Accessed 10 October 2001.
7.
Kaiser Permanente. Welcome to Kaiser Permanente. Available from http://www.kaiserpermanente.org/index.html. Accessed 10 October 2001.
8.
Veterans Affairs. Health benefits and services. Available from http://www.va.gov/vbs/health/. Accessed 10 October 2001.
9.
Jaggers LD.Differentiation of critical pathways from other health care management tools. Am J Health-Syst Pharm1996; 53: 311-313.
10.
Browman GP, Levine MN, Mohide EA, et al.The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol1995; 13: 502-512.
11.
Shekelle PG, Ortiz E, Rhodes S, et al.Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?JAMA2001; 286: 1461-1467.
12.
Rosser WW.The place of guidelines and their means of dissemination. Can J Clin Pharmacol2001; 8(Suppl A): 34A-38A.
13.
Donabedian A.Explorations in quality assessment and monitoring: Vol. I. The definition of quality and approaches to its assessment. Ann Arbor, MI: Health Administration Press, 1980.
14.
Kramer S, Meadows AT, Pastore G, et al.Influence of place of treatment on diagnosis, treatment, and survival in three pediatric solid tumors. J Clin Oncol1984; 2: 917-923.
15.
Norum J, Nordoy T, Wist E.Testicular cancer treated in a minor general oncology department [see comments]. Eur J Cancer1995; 31A: 293-295.
16.
Nolan TW.System changes to improve patient changes. BMJ2000; 320: 771-773.
17.
de Lemos M.Chemotherapy regimens have been formalised into protocols in British Columbia. BMJ2001; 322: 1424-1424. Letter.
18.
Pritchard J, Stiller CA, Lennox EL.Overtreatment of children with Wilms’ tumour outside paediatric oncology centres. BMJ1989; 299: 835-836.
19.
Collette L, Sylvester RJ, Stenning SP, et al.Impact of the treating institution on survival of patients with ‘poor-prognosis’ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party [see comments]. J Natl Cancer Inst1999; 91: 839-846.
20.
Trudeau ME, Eisenhauer ES, Higgins BP, Letendre F, et al.Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol1996; 14: 422-428.
21.
Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, et al.Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol2000; 18: 562-562.
22.
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, et al.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med1993; 328: 1002-1006.
23.
McKelvey EM, Gottlieb JA, Wilson HE, Haut A, et al.Hydroxyldaunomycin (Adriamycin) combination therapy in malignant lymphoma. Cancer1976; 38: 484-493.
24.
Coiffier B, Lepage E, Herbrecht R, Tilly H, et al.Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood2000; 96: 223a-223a. Abstract 950.
